

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Lysine-specific demethylase 2 (KDM2); KDM7	<p><i>In vitro</i> and cell culture studies identified a hydroxamate-based inhibitor of KDM2 and KDM7 that could help treat cancer. <i>In vitro</i> and computational modeling studies identified a compound that inhibited KDM2 and KDM7 at low or submicromolar concentrations. In cancer cell lines, the compound decreased proliferation compared with no treatment. Next steps include testing the compound in xenograft mouse models of cancer.</p> <p>SciBX 6(37); doi:10.1038/scibx.2013.1025 Published online Sept. 26, 2013</p>	Patent application filed; available for licensing	<p>Suzuki, T. <i>et al. J. Med. Chem.</i>; published online Aug. 21, 2013; doi:10.1021/jm400624b</p> <p>Contact: Naoki Miyata, Nagoya City University, Nagoya, Japan e-mail: miyata-n@phar.nagoya-cu.ac.jp</p> <p>Contact: Tamio Mizukami, Nagahama Institute of Bio-Science and Technology, Shiga, Japan e-mail: mizukami@nagahama-i-bio.ac.jp</p> <p>Contact: Takayoshi Suzuki, Kyoto Prefectural University of Medicine, Kyoto, Japan e-mail: suzukit@koto.kpu-m.ac.jp</p>